Vincerx Pharma (VINC) Short Interest Ratio & Short Volume

Short interest is the volume of Vincerx Pharma shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 133,300 shares of VINC short. 2.97% of Vincerx Pharma's shares are currently sold short. Learn More on Vincerx Pharma's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.97% of Vincerx Pharma's floating shares are currently sold short.

Vincerx Pharma saw a decline in short interest in April. As of April 15th, there was short interest totaling 133,300 shares, a decline of 2.8% from the previous total of 137,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Vincerx Pharma currently has issued a total of 5,234,000 shares. Some of Vincerx Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Vincerx Pharma currently has a public float of 4,490,000 shares.

2.97% of Vincerx Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Vincerx Pharma: GRI Bio, Inc. (34.61%), Aptevo Therapeutics Inc. (23.30%), Windtree Therapeutics, Inc. (8.89%), Viracta Therapeutics, Inc. (0.66%), Avenue Therapeutics, Inc. (2.95%), Syros Pharmaceuticals, Inc. (17.70%), Biora Therapeutics, Inc. (6.64%), Virpax Pharmaceuticals, Inc. (26.21%), TFF Pharmaceuticals, Inc. (3.95%), TC Biopharm (Holdings) Plc (176.43%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks.

Short selling VINC is an investing strategy that aims to generate trading profit from Vincerx Pharma as its price is falling. VINC shares are trading up $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Vincerx Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of VINC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VINC, twice per month. The most recent reporting period available is April, 15 2025.